Medical Treatment of Breast Cancer Bone Metastasis: From Bisphosphonates to Targeted Drugs
Küçük Resim Yok
Tarih
2014
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Asian Pacific Organization Cancer Prevention
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Breast cancer bone metastasis causing severe morbidity is commonly encountered in daily clinical practice. It causes pain, pathologic fractures, spinal cord and other nerve compression syndromes and life threatening hypercalcemia. Breast cancer metastasizes to bone through complicated steps in which numerous molecules play roles. Metastatic cells disrupt normal bone turnover and create a vicious cycle to which treatment efforts should be directed. Bisphosphonates have been used safely for more than two decades. As a group they delay time to first skeletal related event and reduce pain, but do not prevent development of bone metastasis in patients with no bone metastasis, and also do not prolong survival. The receptor activator for nuclear factor kappa B ligand inhibitor denosumab delays time to first skeletal related event and reduces the skeletal morbidity rate. Radionuclides are another treatment option for bone pain. New targeted therapies and radionuclides are still under investigation. In this review we will focus on mechanisms of bone metastasis and its medical treatment in breast cancer patients.
Açıklama
Anahtar Kelimeler
Breast Cancer, Bone Metastasis, Bisphosphonates, Denosumab, Targeted Therapy, Phase-Ii Trial, Skeletal-Related Event, Zoledronic Acid, Double-Blind, Risk-Factors, Multiple-Myeloma, Prostate-Cancer, Pain Palliation, Osteoclast Formation, Oral Ibandronate
Kaynak
Asian Pacific Journal Of Cancer Prevention
WoS Q Değeri
Q3
Scopus Q Değeri
Q3
Cilt
15
Sayı
4
